Substance use disorder is the diagnostic term used in the DSM-5 — the Diagnostic and Statistical Manual of Mental Disorders — to describe a pattern of using alcohol or other substances that leads to clinically significant impairment or distress. It replaced earlier terminology like “substance abuse” and “substance dependence” and is now the standard clinical, billing, and regulatory language across behavioral health. For treatment centers, the term shapes everything from how conditions are coded on insurance claims to how content is written to reach people searching for help.

What Substance Use Disorder Means Clinically

The DSM-5 defines substance use disorder across eleven criteria — including loss of control over use, continued use despite consequences, tolerance, withdrawal, and social and functional impairment — with severity classified as mild, moderate, or severe based on how many criteria are present. The diagnosis applies across substance categories: alcohol, opioids, stimulants, cannabis, sedatives, and others, each with its own diagnostic specification.

Severity classification matters for treatment because it influences level of care recommendations and payer authorization criteria. A patient meeting two or three criteria may be appropriate for outpatient intervention. A patient meeting six or more, particularly with physiological dependence, is more likely to require a higher level of care — detox, residential, or intensive outpatient support. Clinical placement decisions grounded in DSM-5 severity are more defensible to payers than those based on clinical intuition alone.

Co-Occurring Disorders

Substance use disorder frequently co-occurs with psychiatric conditions — depression, anxiety, PTSD, bipolar disorder — a presentation referred to as dual diagnosis or co-occurring disorders. Co-occurring presentations are the norm rather than the exception in most treatment populations. Facilities that assess and treat both conditions simultaneously produce better outcomes and are better positioned to serve the full clinical complexity of their patient population. From a marketing standpoint, co-occurring disorder capability is a clinical differentiator that affects which prospective patients choose a facility — and it’s a meaningful SEO opportunity given the significant search volume around dual diagnosis treatment.

Why the Clinical Definition Matters for Marketing

How a facility describes addiction in its marketing content carries real consequences. Using outdated terminology — “substance abuse,” “addict,” “junkie” — in patient-facing content signals a lack of clinical currency that damages credibility with both prospective patients and with Google’s quality assessment of health content. Using person-first language (“person with a substance use disorder” rather than “addict”) and DSM-5 diagnostic terminology signals clinical competence and reduces stigma in a way that resonates with treatment-seeking audiences.

E-E-A-T requirements for behavioral health content mean that Google evaluates treatment center pages partly on clinical accuracy and professional credibility. Content that uses the correct diagnostic terminology, reflects current clinical understanding of addiction as a chronic brain disorder, and is reviewed by credentialed clinicians ranks better than content built on outdated or stigmatizing language — because it better serves the people searching for it.

Search behavior around substance use disorder also reflects clinical terminology more than colloquial language among people who have already engaged with the healthcare system. A person researching treatment for themselves after a clinical encounter will search using the language their provider used — which is increasingly DSM-5 terminology. Content targeting those searches needs to reflect that language.

Why the Billing Definition Matters for Revenue

Substance use disorder diagnoses translate to ICD-10 codes on insurance claims — the billing codes that identify what condition is being treated and at what severity. Accurate, specific coding that reflects the DSM-5 diagnosis and severity level is foundational to clean claims and appropriate reimbursement.

Coding accuracy affects several downstream revenue variables. Under-coding — using a less specific or lower-severity code than the clinical presentation supports — can result in lower reimbursement than the facility is entitled to. Incorrect coding — using codes that don’t match the documented clinical presentation — creates claims that are vulnerable to audit and denial. The specificity of the substance use disorder diagnosis in the medical record needs to match the specificity of the codes submitted on the claim, which requires clinical documentation that captures the DSM-5 criteria, severity level, and specific substance category with precision.

Prior authorization requests also need to reflect the substance use disorder diagnosis accurately. Payers applying ASAM criteria to authorization decisions are evaluating the clinical presentation documented by the facility — and that documentation needs to clearly establish the severity and complexity that supports the requested level of care.

What Good Looks Like — and Where Most Facilities Go Wrong

Facilities that handle substance use disorder accurately across marketing, clinical documentation, and billing have content that uses current clinical terminology, assessment processes that capture DSM-5 criteria at admission, and billing workflows that code diagnoses with the specificity that supports reimbursement.

Common failures:

Outdated terminology in patient-facing content. “Drug abuse,” “substance abuse,” and similar terms persist in treatment center content because they’re familiar — but they reflect a pre-DSM-5 diagnostic framework that clinical professionals and informed patients recognize as outdated. Auditing existing content for terminology and updating to current clinical language is both an E-E-A-T improvement and a patient experience one.

Clinical assessments that don’t document DSM-5 criteria explicitly. An intake assessment that describes a patient’s substance use history without systematically documenting the specific DSM-5 criteria met produces clinical records that are difficult to defend to payers evaluating authorization requests. Assessment tools that map directly to DSM-5 criteria produce documentation that supports both clinical decision-making and payer authorization.

Coding at the category level without substance specificity. ICD-10 has specific codes for substance use disorder by substance type and severity. Coding all substance use disorder as a generic category rather than specifying the substance and severity level — alcohol use disorder, severe; opioid use disorder, moderate — misses reimbursement precision that accurate coding provides.